Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecule therapeutics that target fundamental biological pathways of cancers. The company's mission is to advance innovative oncology treatments to improve the lives of patients facing difficult-to-treat cancers. Zentalis Pharmaceuticals is headquartered in San Diego, California.

The company's primary product candidate is azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor. This therapeutic is being developed for various oncologic indications, with a significant focus on Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Azenosertib works by inhibiting WEE1, a DNA damage response kinase, which forces cancer cells into mitosis without repairing damaged DNA, leading to cell death and preventing tumor growth. It is being evaluated both as a monotherapy and in combination across multiple tumor types.

In recent developments, Zentalis Pharmaceuticals made a strategic pivot in 2025 to concentrate resources almost entirely on azenosertib, a move that included a workforce reduction and extended its cash runway into late 2027. Julie Eastland serves as the Chief Executive Officer, having been appointed in November 2024. The company announced in April 2026 the selection of 400mg QD 5:2 azenosertib monotherapy as the pivotal study dose for Cyclin E1-positive platinum-resistant ovarian cancer. Topline results from the DENALI Part 2 trial, which could support accelerated approval, are anticipated by the end of 2026.